Skip to content

Depression: all studies

Page 905 of 1,034: studies 9,041 to 9,050 of 10,336, newest first. Back to the depression overview

Research

1075 VERBAL MEMORY FUNCTIONING MODERATES RESPONSE TO TREATMENT FOR RECURRENT NIGHTMARES IN PTSD

Sleep April 28, 2017 JC Scott, GC Harb, JA Brownlow et al.

Imagery rehearsal therapy (IR) is arguably the most effective form of cognitive-behavioral therapy (CBT) for the prominent nightmare disturbance in PTSD. CBT for insomnia (CBT-I) may also have efficacy for treating this problem. Although PTSD is associated with cognitive deficits in attention, executive control, and retrospective memory, functions likely essential to CBT outcome, no study has...

0730 EFFECT OF EVERYDAY ANXIETY AND PSYCHOLOGICAL WELL-BEING ON THE RECALL OF DISTURBED DREAMING

Sleep April 28, 2017 Cristina Banu, Pierre McDuff, Antonio Zadra 1 citation

The present study tested a prediction from Levin and Nielsen’s (2007) neurocognitive model of disturbed dreaming stipulating that variations in the frequency of bad dreams and nightmares are partly determined by day-to-day variations in emotional stress. The model also suggests that relations between dreams and stress may vary as a function of personality traits. 224 adults (186F, 38M, mean...

ПСИХОТИЧЕСКИЕ РАССТРОЙСТВА У ЛИЦ, УПОТРЕБЛЯЮЩИХ СИНТЕТИЧЕСКИЕ КАННАБИНОИДЫ (СПАЙСЫ)

April 28, 2017 Иванова Людмила Александровна, Терских Татьяна Владимировна, Тарасенко Татьяна Владимировна et al.

The study involved the group of patients (n = 40) with psychotic disorders who used synthetic cannabinoids (spice). Among the psychotic disorders according to ICD-10 we allocated intoxication delirium (F12.03; 35 %), schizophreniform disorder (F12.50; 60 %), disorder with predominantly manic psychotic symptoms (F12.55; 5 %). The average age of patients was 25.2 ± 4.4 years. Hereditary...

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

Scientific Reports April 27, 2017 Isaac Cohen, Tigran Makunts, Rabia Samady Atayee et al. 27 citations

Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence. Here we provide new support for the antidepressant effect of an anesthetic drug, ketamine, by Inverse-Frequency Analysis of eight million reports from the FDA Adverse Effect Reporting System. The results of the examination of population scale data revealed that patients...

A Pilot Study of Mindfulness Meditation for Pediatric Chronic Pain

Children April 26, 2017 Lynn C Waelde, Amanda Feinstein, Rashmi Bhandari et al.

Despite advances in psychological interventions for pediatric chronic pain, there has been little research examining mindfulness meditation for these conditions. This study presents data from a pilot clinical trial of a six-week manualized mindfulness meditation intervention offered to 20 adolescents aged 13–17 years. Measures of pain intensity, functional disability, depression and parent...

Meditation awareness training for the treatment of workaholism: A controlled trial

Journal of Behavioral Addictions April 19, 2017 William van Gordon, Edo Shonin, Thomas J. Dunn et al. 144 citations

Background and aims Workaholism is a form of behavioral addiction that can lead to reduced life and job satisfaction, anxiety, depression, burnout, work-family conflict, and impaired productivity. Given the number of people affected, there is a need for more targeted workaholism treatments. Findings from previous case studies successfully utilizing second-generation mindfulness-based...

Should addiction researchers be interested in psychedelic science?

Drug and Alcohol Review April 10, 2017 Stephen Bright, M.l. Williams, David Caldicott 5 citations

As recently noted by Strauss, Bright and Williams 1, while much of the Western world has been experiencing a renaissance in research into ‘psychedelic science’ over the past decade 2, there has been no such research conducted in Australia. In Europe and the USA, studies have been conducted into lysergic acid diethylamide (LSD) that have improved our understanding of brain function 3 and reduced...

A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial

Trials April 4, 2017 Amy Mcandrew, Will Lawn, Tobias Stevens et al. 20 citations

BACKGROUND: Worldwide, alcohol abuse is a burgeoning problem. Abstinence is key to allow recovery of physical and mental health as well as quality of life, but treatment for alcohol dependence is associated with high relapse rates. Preliminary data have suggested that a combined repeated ketamine and psychological therapy programme may be effective in reducing relapse in severe alcohol use...

A Comparison of Mindfulness-Based Group Training and Skills Group Training in Adults With ADHD

Journal of Attention Disorders April 1, 2017 Marc-Andreas Edel, Tanja Hölter, Kristina Wassink et al.

Objective: To compare a novel “third wave” mindfulness-based training program with an established skills training derived from dialectical behavior therapy, to reduce ADHD symptoms and improve mindfulness and self-efficacy. Method: Ninety-one adults with ADHD (combined and inattentive type, mainly medicated) were non-randomly assigned to and treated within a mindfulness-based training group...

Antidepressant‐like Effects of Ketamine in Serotonin Transporter Knockout Mice and Organic Cation Transporter 3 Knockout Mice

The FASEB Journal April 1, 2017 Melodi Ann Bowman, Melissa Vitela, W. Anthony Owens et al.

Twenty percent of adults are diagnosed with major depressive disorder, which is typically treated with selective serotonin reuptake inhibitors. However, this type of medication takes approximately six weeks to produce therapeutic effects. Recently, low doses of ketamine, a noncompetitive N‐methyl‐D‐aspartate (NMDA) receptor antagonist, have been shown to produce rapid and long‐lasting...